Table 2 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors

Puntos clave

• Adverse events related to basroparib were summarized, indicating outcomes of treatment.
• Patients with advanced-stage solid tumors showed varying responses during dose-escalation.
• The phase I study evaluated the safety and tolerability of basroparib.
• Considering the advanced-stage tumors, findings support ongoing research into tankyrase inhibitors.